Van Eck Associates Corp Incyte Corp Transaction History

Van Eck Associates Corp

$70.4 Billion
Q2 2024

A detailed history of Van Eck Associates Corp transactions in Incyte Corp stock. As of the latest transaction made, Van Eck Associates Corp holds 161,993 shares of INCY stock, worth $10.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

161,993

Previous 156,972 3.2%

Holding current value

$10.7 Million

Previous $8.94 Million 9.82%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	BUY	$51.18 - $63.75 $256,974 - $320,088	5,021 Added 3.2%	161,993 $9.82 Million
Q1 2024 Apr 30, 2024	BUY	$56.55 - $66.59 $24,429 - $28,766	432 Added 0.28%	156,972 $8.94 Million
Q4 2023 Feb 05, 2024	SELL	$52.16 - $64.19 $1.98 Million - $2.44 Million	-37,941 Reduced 19.51%	156,540 $9.83 Million
Q3 2023 Nov 08, 2023	BUY	$57.77 - $65.93 $700,345 - $799,269	12,123 Added 6.65%	194,481 $11.2 Million
Q2 2023 Aug 03, 2023	BUY	$60.95 - $75.51 $425,552 - $527,210	6,982 Added 3.98%	182,358 $11.4 Million
Q1 2023 May 03, 2023	SELL	$70.23 - $86.01 $2.74 Million - $3.36 Million	-39,039 Reduced 18.21%	175,376 $12.7 Million
Q4 2022 Feb 08, 2023	BUY	$67.18 - $84.11 $2.91 Million - $3.64 Million	43,245 Added 25.26%	214,415 $17.2 Million
Q3 2022 Oct 27, 2022	SELL	$66.18 - $82.86 $3.73 Million - $4.67 Million	-56,324 Reduced 24.76%	171,170 $11.4 Million
Q2 2022 Aug 03, 2022	BUY	$66.18 - $83.18 $2.38 Million - $2.99 Million	35,933 Added 18.76%	227,494 $17.3 Million
Q1 2022 May 10, 2022	BUY	$66.02 - $79.71 $2.66 Million - $3.22 Million	40,360 Added 26.69%	191,561 $15.2 Million
Q4 2021 Jan 26, 2022	SELL	$63.34 - $74.11 $1.11 Million - $1.29 Million	-17,464 Reduced 10.35%	151,201 $11.1 Million
Q3 2021 Nov 03, 2021	SELL	$68.67 - $84.02 $2.16 Million - $2.64 Million	-31,467 Reduced 15.72%	168,665 $11.6 Million
Q2 2021 Aug 10, 2021	BUY	$79.87 - $87.53 $619,152 - $678,532	7,752 Added 4.03%	200,132 $16.8 Million
Q1 2021 May 13, 2021	SELL	$76.02 - $100.5 $1.11 Million - $1.47 Million	-14,596 Reduced 7.05%	192,380 $15.6 Million
Q4 2020 Feb 09, 2021	BUY	$80.74 - $97.7 $795,208 - $962,247	9,849 Added 5.0%	206,976 $18 Million
Q3 2020 Nov 12, 2020	SELL	$85.07 - $109.69 $3.26 Million - $4.2 Million	-38,287 Reduced 16.26%	197,127 $17.7 Million
Q2 2020 Aug 10, 2020	BUY	$74.18 - $108.93 $3.3 Million - $4.84 Million	44,439 Added 23.27%	235,414 $24.5 Million
Q1 2020 May 12, 2020	BUY	$63.18 - $85.97 $1.33 Million - $1.81 Million	20,996 Added 12.35%	190,975 $14 Million
Q4 2019 Feb 13, 2020	SELL	$73.04 - $95.72 $1.41 Million - $1.85 Million	-19,293 Reduced 10.19%	169,979 $14.8 Million
Q3 2019 Nov 08, 2019	SELL	$72.82 - $86.52 $1.4 Million - $1.66 Million	-19,183 Reduced 9.2%	189,272 $14.1 Million
Q2 2019 Aug 07, 2019	SELL	$73.52 - $88.7 $752,036 - $907,312	-10,229 Reduced 4.68%	208,455 $17.7 Million
Q1 2019 May 13, 2019	SELL	$63.56 - $88.17 $3.05 Million - $4.23 Million	-47,968 Reduced 17.99%	218,684 $18.8 Million
Q4 2018 Feb 12, 2019	SELL	$58.5 - $69.94 $459,517 - $549,378	-7,855 Reduced 2.86%	266,652 $17 Million
Q3 2018 Nov 13, 2018	BUY	$61.75 - $74.23 $442,685 - $532,154	7,169 Added 2.68%	274,507 $19 Million
Q2 2018 Aug 13, 2018	BUY	$60.85 - $83.98 $2.73 Million - $3.77 Million	44,910 Added 20.19%	267,338 $17.9 Million
Q1 2018 May 11, 2018	SELL	$83.06 - $100.98 $4.67 Million - $5.67 Million	-56,189 Reduced 20.17%	222,428 $18.5 Million
Q4 2017 Feb 12, 2018	BUY	$93.56 - $116.6 $3.64 Million - $4.54 Million	38,902 Added 16.23%	278,617 $26.4 Million
Q3 2017 Nov 09, 2017	SELL	$109.15 - $138.27 $415,643 - $526,532	-3,808 Reduced 1.56%	239,715 $28 Million
Q2 2017 Aug 11, 2017	BUY	N/A	243,523	243,523 $30.7 Million

Others Institutions Holding INCY

# of Institutions

629

Shares Held

198M

Call Options Held

766K

Put Options Held

476K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $14.7B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Van Eck Associates Corp, based on Form 13F filings with the SEC.

News

Stay updated on Van Eck Associates Corp with notifications on news.

Account

Van Eck Associates Corp Incyte Corp Transaction History